Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	63.25L 0 56.2L 52.45L 47.81L 90.16L 61Cr 91L 6.35Cr 2.46Cr 31Cr 2.37Cr 2.32Cr 100Cr	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	63.25L 0 56.2L 52.45L 47.81L 90.16L 61Cr 91L 6.35Cr 2.46Cr 31Cr 2.37Cr 2.32Cr 100Cr	EV / Sales 2026 *	4.4x	EV / Sales 2027 *	2.43x
Free-Float	72.14%	Yield 2026 *	-	Yield 2027 *	-

16/09	Evogene Ltd. Announces Board Changes	CI
11/09	L.I.A. Pure Capital Intends to Commence a Special Tender Offer to Evogene	CI
04/09	Evogene Ltd. Approves Board Appointments	CI
28/08	L.I.A. Pure Capital Issues Response to Evogene	CI
25/08	Institutional Shareholder Services and Glass Lewis Makes Recommendations to Shareholders	CI
18/08	Evogene Ltd., Q2 2026 Earnings Call, Aug 18, 2026
18/08	Evogene Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
17/08	Freightos Names Yaron Eldad as Chief Financial Officer	MT
27/07	L.I.A. Pure Capital Ltd Delivers an Email to Evogene Ltd	CI
22/07	Evogene Ltd. and Eleo Inc. Announce Collaboration to Develop Next-Generation Oral Small-Molecule Pcsk9 Pathway Inhibitors for Hyperlipidemia and Cardiovascular Diseases	CI
22/07	Evogene, ELEO Collaborating to Develop Oral PCSK9 Inhibitors	MT
10/07	L.I.A. Pure Capital Sends Letter to Evogene	CI
08/07	Evogene Ltd. and Blavatnik Center For Drug Discovery at Tel Aviv University Announce Joint Initiative to Accelerate AI-Driven Small-Molecule Drug Discovery	CI

02/23/02	Alliance Global Starts Evogene at Buy With $1.85 Price Target	MT
18/23/18	Lake Street Adjusts Evogene's Price Target to $3 From $2, Keeps Buy Rating	MT
29/21/29	Evogene : Aegis Capital Starts Evogene at Buy	MT
01/20/01	Evogene : Cantor Fitzgerald Starts Evogene at Overweight With $9 Price Target	MT

30/09	Evogene Reports Nasdaq Grants Additional 180-Day Period to Regain Minimum Bid Price Compliance	PR
31/08	Evogene Responds to Dissident Shareholders: Transformation and Commercial Progress Provide a Clear Path Forward	PR
25/08	Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Evogene Ltd. Shareholders Vote "FOR" the Company's Slate of Highly Qualified Director Nominees	PR
18/08	Evogene Reports Second Quarter and First Half 2026 Financial Results	PR
18/08	Evogene : Reports Second Quarter and First Half 2026 Financial Results	PU

Manager	Title	Age	Since
Ofer Haviv CEO	Chief Executive Officer	60	01/12/2004
Gabi Tarcic PRN	Corporate Officer/Principal	-	-
Polina Ravzin PRN	Corporate Officer/Principal	-	01/01/2022

Evogene Ltd Share Price TEL AVIV STOCK EXCHANGE

Stocks

IL0011050551

Biotechnology & Medical Research

Valuation: Evogene Ltd

Latest news: Evogene Ltd

Last Transcript: Evogene Ltd

Analysts' recommendations: Evogene Ltd

Press Releases: Evogene Ltd

News in other languages: Evogene Ltd

Quotes and Performance

Managers and Directors: Evogene Ltd

Other Biotechnology & Medical Research

Financials

Company Profile

Director	Title	Age	Since
Ofer Haviv BRD	Director/Board Member	60	-
Leon Recanati BRD	Director/Board Member	77	03/06/2010
Sarit Firon CHM	Chairman	60	01/06/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EVOGENE LTD	-0.43%	-5.52%	-	-	63.82L
WUXI APPTEC CO., LTD.	+4.16%	+3.04%	+49.37%	+94.17%	7.42TCr
ARGENX SE	-3.11%	-3.53%	+21.92%	+74.60%	5.74TCr
LONZA GROUP AG	+0.89%	-0.63%	+4.28%	+34.51%	4.76TCr
REVOLUTION MEDICINES, INC.	+0.36%	+0.81%	+352.17%	+689.61%	4.43TCr
IQVIA HOLDINGS INC.	-0.96%	-4.50%	+26.36%	+33.18%	4.25TCr
BEONE MEDICINES AG	-0.20%	-0.77%	+3.74%	+100.60%	4.07TCr
CELLTRION, INC.	-0.54%	+2.93%	+9.31%	+50.41%	3.1TCr
WUXI BIOLOGICS (CAYMAN) INC.	-2.68%	+2.92%	+29.63%	+19.50%	2.85TCr
BIONTECH SE	+0.05%	-1.64%	-7.28%	-14.06%	2.43TCr
Average	-0.25%	-0.59%	+54.39%	+120.28%	4.34TCr
Weighted average by Cap.	+0.12%	-0.84%	+58.77%	+129.91%

	2026 *	2027 *
Net sales	14.36L 0 12.76L 11.91L 10.85L 20.47L 14Cr 20.66L 1.44Cr 55.84L 7.06Cr 53.91L 52.74L 23Cr	26L 0 23.1L 21.56L 19.65L 37.06L 25Cr 37.41L 2.61Cr 1.01Cr 13Cr 97.62L 95.5L 41Cr
Net income	-1.22Cr -0 -1.08Cr -1.01Cr -91.98L -1.73Cr -116.98Cr -1.75Cr -12Cr -4.73Cr -60Cr -4.57Cr -4.47Cr -191.93Cr	-1.02Cr -0 -90.63L -84.59L -77.1L -1.45Cr -98Cr -1.47Cr -10Cr -3.97Cr -50Cr -3.83Cr -3.75Cr -160.88Cr
Net Debt	-	-